|
CN107709351A
|
|
Cytotoxic t cell epitope peptide for sars and application thereof
|
|
EP2573175A2
|
|
ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
|
|
WO2011074621A1
|
|
Mesothelin (msln) antibody and use thereof
|
|
EP2322610A1
|
|
Anti-human clcp1 antibody and use thereof
|
|
WO2007119808A1
|
|
Fusion partner cells
|
|
EP2011870A1
|
|
Mutant polypeptide having effector function
|
|
US2009142363A1
|
|
Cytotoxic t-cell epitope peptide and use thereof
|
|
WO2006025526A1
|
|
Process for producing dendritic cell having acquired ctl inducing capability
|
|
WO2006025525A1
|
|
Method of selecting protein easily undergoing antigen-presentation by dendritic cells
|
|
US2008248011A1
|
|
Methods for Isolating Monocytes
|
|
WO2005068504A1
|
|
Inflammatory cytokine inhibitor
|
|
US2007059784A1
|
|
Methods for measuring the insulin receptor α subunit
|
|
WO2004061452A1
|
|
Method of assaying antibody
|
|
AU5678901A
|
|
Method of assaying anti-ena antibody and assay kit
|
|
AU1887101A
|
|
Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
|
